Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 (AMG 232) + KRd in Relapsed/Refractory Multiple Myeloma
NCT03031730Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navtemadlin in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Safety and Tolerability at 6 months and Maximum Tolerated Dose and Recommended Phase 2 Dose at 6 months. Started Jun 2018; status: terminated.
02
Drugs
navtemadlin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03031730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031730.